New Street Research - WISE PLC (WISE) WISE (Neutral, TP: £6.85, +1%) WISE - Q1 trading update: No big surprises (though strong adds and NII a touch ahead)

Report

New Street Research

Soomit Datta

EUR 9461.00 For Business Accounts Only

WISE (Neutral, TP: £6.85, +1%) WISE - Q1 trading update: No big surprises (though strong adds and NII a touch ahead)

WISE’s Q1 trading update (revenue only, no profitability) had been pretty well flagged at the recent FYs (only three weeks ago) so there were no material surprises. With that said, net adds came in ahead on Personal (500k for the quarter is the strongest level for some time) whilst NII also beat expectations (by £10m), which will be supportive for near-term EBITDA.

18/07/2023 1 EN

Underlying

WISE PLC

See profile

GB00BL9YR756 London Stock Exchange United Kingdom

Provider

New Street Research

Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.

New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:

Pan European Telecom Services and Cable
US Telecoms, Cable, Satellite and Towers
Global Emerging Market Telecoms
Japan Telecoms
Asian Internet
Pan European Healthcare
Global healthcare thematic research

We provide debt research on:

Pan European Telecom Services and Cable

See profile

Analysts

Soomit Datta

Other Reports on these Companies

New Street Research

WISE (BUY, TP: £9.00, +15%) WISE - H1 25 and Platform deal bang on cue; from billions to trillions

WISE’s full H1 release this morning filled in the lower half of the P&L after interims and gross margin had been pre-released.

EUR 9461.00

November 6, 2024 November 6, 2024 1 EN

New Street Research

WISE (BUY, TP: £9.00, +30%) WISE H1 25 - Upgrade to BUY: Good entry point for Platform Opportunity

WISE’s trading statement this morning reflected the second of two sizeable price cuts this year (late-August). These reflect structural revisions down in the cost base; we appear done now on pricing for the foreseeable future. Gross profit margin is also trending ahead on structural efficiencies (with more to come from syncing into PIX in Brazil).

EUR 9461.00

October 15, 2024 October 15, 2024 1 EN

New Street Research

WISE (Neutral, TP: £8.00, +5%) WISE Q1 25 trading statement: Nice beat, after expectations reset

This morning’s Q1 25 Trading statement showed better volumes (a 3% beat), revenue (2%) and underlying income (1%) than expected (NSR and consensus); there is no profitability reported. Of particular significance was the volume improvement, with momentum here having been weak of late as WISE gravitates to more “card usage” from core transfer customers. The fall in the cross-border take-rate, meanwhile, had been well flagged following April price cuts.

EUR 9461.00

July 16, 2024 July 16, 2024 1 EN

TalkTalk H1 results: Guidance looks at risk

TalkTalk has reported its H1 results to August, albeit given the lack of an investor presentation, it is hard to decipher all the changes vs. their guidance at this stage, but we think the numbers are at the low end of any prior guidance. We are still also critically waiting for any disclosure on KPIs since February, but we think the risk is to the downside given Openreach disclosure.

EUR 9461.00

5h / 17m 5h / 17m 1 EN

Russell Waller

Russell Waller

Odido (T-Mobile NL) (Equal Weight) Q3 24: Positioned nicely for a possible IPO in 2025

SR trends continue to slide in aggregate, but Odido claimed that 2024 was always going to be a tough year for KPIs and SR (rebrand, T2 switch-off and commercial channel refurb), and talked confidently about the outlook for SR thanks to a mobile recovery (with a target of better postpaid adds going forward, so that it can take its “fair share of market growth”), and fixed gains.

EUR 9461.00

5h / 56m 5h / 56m 1 EN

Dominic Rose ... (+2)

Dominic Rose
Naresh Chouhan

EU Pharma 2025 Outlook - The Correction Was Due, Tread Carefully

In the aftermath of the H224 Healthcare correction, we look forward to 2025 with a more focused stock specific approach We show sector fundamentals have remained robust despite the correction. We see 4 key themes for the Pharma sector in 2025; 1) 2025 is a very strong year for important pipeline readouts, 2) The volume impact of Medicare Part D reform will dominate the narrative in H125 & continue to be a tailwind into 2026, 3) Margin expansion should be robust at a sector level, 4) Biotech M&A is likely to be materially higher than in 2024. As a result of these dynamics we change a number of...

EUR 4730.50

12h / 12m 12h / 12m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

WISE (Neutral, TP: £6.85, +1%) WISE - Q1 trading update: No big surprises (though strong adds and NII a touch ahead)

WISE (BUY, TP: £9.00, +15%) WISE - H1 25 and Platform deal bang on cue; from billions to trillions

WISE (BUY, TP: £9.00, +30%) WISE H1 25 - Upgrade to BUY: Good entry point for Platform Opportunity

WISE (Neutral, TP: £8.00, +5%) WISE Q1 25 trading statement: Nice beat, after expectations reset

TalkTalk H1 results: Guidance looks at risk

Odido (T-Mobile NL) (Equal Weight) Q3 24: Positioned nicely for a possible IPO in 2025

EU Pharma 2025 Outlook - The Correction Was Due, Tread Carefully

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe